Alkermes settles Lybalvi patent suit with Teva, licenses generic entry for 2039
Alkermes and Teva resolved ANDA litigation over Lybalvi, with Teva's generic allowed to launch starting November 12, 2039, subject to antitrust review.
SEC filing (2)
1 story
Alkermes and Teva resolved ANDA litigation over Lybalvi, with Teva's generic allowed to launch starting November 12, 2039, subject to antitrust review.
SEC filing (2)